DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Microscopic Polyangiitis (MPA) - Pipeline Review, H1 2017" report to their offering. Pharmaceutical and Healthcare ...
On Amgen's call, the company's head of R&D, Jay Bradner, said the FDA's request for a voluntary withdrawal on 16th January ...
CHMP is reviewing avacopan, a drug authorized in the EU for treating adults with severe, active granulomatosis with polyangiitis or microscopic polyangiitis.
Please provide your email address to receive an email when new articles are posted on . SAN DIEGO — Patients with granulomatosis with polyangiitis and microscopic polyangiitis who lower their ...
MedPage Today on MSN
FDA Wants Drug Pulled From Market, Citing Liver Risk. Company Says No.
Agency raised questions about avacopan's pivotal trial data and concerns of hepatotoxicity ...
EMA begins review of Tavneos, a medicine for rare autoimmune diseases GPA and MPA: Amsterdam, The Netherlands Monday, February 2, 2026, 14:00 Hrs [IST] European Medicines Agencys ...
The prophylactic efficacy of TMP-SMX was significantly higher in subgroups with baseline lymphopenia, azotemia, microscopic polyangiitis, or relapsed AAV. Prophylactic use of ...
"EMA will now review all available data to assess whether this emerging information has an impact on the balance of benefits and risks of Tavneos," said the EU regulator. "The agency will then issue a ...
AAV is a multi-organ disease, which can be complex and may vary from person to person. Types of AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results